Publisher · 2 documents · 17 figures

NMPA (National Medical Products Administration)

17 verified figures from 2 publications by NMPA, a government body. Every figure links to the document and sentence it came from.

Data points
17
Documents
2
Indicators
12
Regions
1
Publisher type
Government

Documents used

Every publication we have taken a number from, with the date we read it and the link status at that time.

Document Type Retrieved Link Data points
Measures facilitate approval of 48 first-in-class innovative drugs Licence: See source Press release 17 Sep 2026 Reachable 11
China approves 48 innovative drugs in 2024 Licence: See source Press release 17 Sep 2026 Reachable 6

Measures from this publisher

Every measure taken from NMPA, with its latest value and trend. Each value opens its record.

Market size and output 5

First-in-class drug approvals China · 2024 48 +20% since 2023 NMPA 4 records
Pediatric medicine approvals China · 2024 106 NMPA 2 records
Rare disease medicine approvals China · 2024 55 NMPA 2 records

Growth and change 1

Other measures 6

12 measures. Each name opens the full series; each value opens the record with its source evidence.

Cite this page

Data on this page is published under CC BY 4.0. Credit National Medical Products Administration as the original publisher; each record page carries its own citation.

National Medical Products Administration. Retrieved from StatOrigin: https://statorigin.org/sources/national-medical-products-administration

Related

Last verified 27 September 2026. Link status is rechecked weekly.